Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Revefenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 19/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Revefenacin SCHEMBL4387596 | 0.97 | CHRM2 (0.94) | CHRM2CHRM3ADRB2 | |
| Revefenacin SCHEMBL4387593 | 0.95 | CHRM2 (0.90) | CHRM2CHRM3ADRB2 | |
| SCHEMBL942211 | 0.94 | CHRM2 (0.88) | CHRM2CHRM3ADRB2 | |
| SCHEMBL31221643 | 0.94 | CHRM2 (0.88) | CHRM2CHRM3ADRB2 | |
| SCHEMBL24274186 | 0.93 | CHRM2 (0.87) | CHRM2CHRM3ADRB2 | |
| SCHEMBL10015122 | 0.93 | CHRM2 (0.87) | CHRM2CHRM3ADRB2 | |
| SCHEMBL942863 | 0.93 | CHRM2 (0.86) | CHRM2CHRM3ADRB2 | |
| SCHEMBL27870690 | 0.92 | CHRM2 (0.86) | CHRM2CHRM3ADRB2 | |
| SCHEMBL5959184 | 0.92 | CHRM2 (0.86) | CHRM2CHRM3ADRB2 | |
| SCHEMBL943273 | 0.92 | CHRM2 (0.85) | CHRM2CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 839 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069601-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | LEXENPHARM SUZHOU LTD (CN) | 2026-03-12 | — | — | US | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| EP-4585215-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | Lexenpharm (Suzhou) Limited (CN) | 2025-07-16 | — | — | EP | claimed |
| US-20250179019-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-06-05 | — | — | US | claimed |
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | THERAVANCE BIOPHARMA R&D IP, LLC | 2025-05-01 | — | — | US | claimed |
| US-12285417-B2 | Methods for treating chronic obstructive pulmonary disease | THERA VANCE BIOPHARMA R&D IP, LLC (US) | 2025-04-29 | — | — | US | claimed |
| US-20250127900-A1 | STABLE PHARMACEUTICAL COMPOSITIONS | MANKIND PHARMA LTD. (IN) | 2025-04-24 | — | — | US | claimed |
| US-20250099692-A1 | METERED-DOSE ATOMIZATION MODULE, ATOMIZER, SPRAY ASSEMBLY AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| US-20250058061-A1 | ATOMIZATION TRIGGER STRUCTURE, AND ATOMIZER HAVING SAME | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-02-20 | — | — | US | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| US-20080095708-A1 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-24 | — | — | US | claimed |
| US-20070298112-A1 | salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid; pulmonary disorders | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-27 | — | — | US | claimed |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-20 | — | — | US | claimed |
| EP-1856050-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| US-7288657-B2 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE, INC. (US) | 2007-10-30 | — | — | US | claimed |
| US-20070112027-A1 | Crystalline forms of a biphenyl compound | THERAVANCE, INC. | 2007-05-17 | — | — | US | claimed |
| EP-1723114-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2006099165-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | CYP4B1, KDM4B, CYP3A4 | CHRM3 1755/4885CHRM2 2542/4885ADRB2 3856/4885 |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885ADRB2 42/4885 |
| US-12285417-B2 | Methods for treating chronic obstructive pulmonary disease | PEF1, CHRM2, PDE12 | CHRM3 6/4885CHRM2 2/4885ADRB2 71/4885 |
| US-20080095708-A1 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 22/4885 |
| US-20070112027-A1 | Crystalline forms of a biphenyl compound | FFAR1, FFAR4, FFAR3 | CHRM3 1386/4885CHRM2 1912/4885ADRB2 2730/4885 |
| US-20260069601-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | ADRB2, ADRB3, CHRM3 | CHRM3 3/4885CHRM2 13/4885ADRB2 1/4885 |
| US-20070298112-A1 | salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid; pulmonary disorders | PLCB1, SLC20A1, SLC34A1 | CHRM3 2945/4885CHRM2 2697/4885ADRB2 1968/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885ADRB2 14/4885 |
| US-20250179019-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | TBCB, FFAR1, CRYAB | CHRM3 494/4885CHRM2 870/4885ADRB2 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.